(Pyrimidin-5-yl)boronic acid → HCID 71535818, compound

HRID 1519350Notes

Reaction equation

HRID 1519350 reaction equation
C[O:2][C:3](=[O:24])[C:4]1[CH:9]=[C:8]([C:10]2[S:11][CH:12]=[C:13]([C:15]3[CH:20]=[CH:19][C:18]([Cl:21])=[C:17]([Cl:22])[CH:16]=3)[N:14]=2)[CH:7]=[CH:6][C:5]=1Br.[N:25]1[CH:30]=[C:29](B(O)O)[CH:28]=[N:27][CH:26]=1>>[Cl:22][C:17]1[CH:16]=[C:15]([C:13]2[N:14]=[C:10]([C:8]3[CH:7]=[CH:6][C:5]([C:29]4[CH:30]=[N:25][CH:26]=[N:27][CH:28]=4)=[C:4]([CH:9]=3)[C:3]([OH:2])=[O:24])[S:11][CH:12]=2)[CH:20]=[CH:19][C:18]=1[Cl:21]

Participants

3

Reactant 2

HCID 2795193(Pyrimidin-5-yl)boronic acidHCID 86679833Methyl 2-bromo-5-(4-(3,4-dichlorophenyl)thiazol-2-yl)benzoate2×

Product 1

HCID 71535818HCID 71535818, compoundYield 16%

Procedure

Using the conditions of General Procedure B for Suzuki Coupling and Hydrolysis in Parallel Mode, 2-bromo-5-[4-(3,4-dichloro-phenyl)-thiazol-2-yl]-benzoic acid methyl ester (which may be prepared as described for Intermediate 6; 89 mg, 0.2 mmol) was reacted with and pyrimidine-5-boronic acid (available from Combi-Blocks Inc.; 50 mg, 0.4 mmol). The resulting ester was hydrolyzed and the acid was purified to give 5-[4-(3,4-dichloro-phenyl)-thiazol-2-yl]-2-pyrimidin-5-yl-benzoic acid (13 mg, 16%). 1H NMR (300 MHz, DMSO-d6) δ 13.42 (br s, 1H), 9.21 (s, 1H), 8.86 (s, 2H), 8.58 (s, 1H), 8.50 (s, 1H), 8.29-8.37 (m, 2H), 8.10 (d, J=8.5 Hz, 1H), 7.77 (d, J=8.5 Hz, 1H), 7.67 (d, J=7.9 Hz, 1H).

Workup

  1. customthe acid was purified

Sources & evidence

ORD record
ord-448eea73cb5945afa59deb8b7093e681
Source dataset
uspto-grants-2015_07
Patent number
US09073881B2

Reaction notes

Loading…